Johannes Merk
Overview
Explore the profile of Johannes Merk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
473
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rivera M, Fichtner I, Wulf-Goldenberg A, Sers C, Merk J, Patone G, et al.
Neoplasia
. 2020 Nov;
23(1):21-35.
PMID: 33212364
Patient-derived xenograft (PDX) tumor models represent a valuable platform for identifying new biomarkers and novel targets, to evaluate therapy response and resistance mechanisms. This study aimed at establishment, characterization and...
2.
Duppel U, Woenckhaus M, Schulz C, Merk J, Dietmaier W
Oncol Lett
. 2016 Oct;
12(4):3004-3012.
PMID: 27698890
Aberrant promoter methylation of tumor relevant genes frequently occurs in early steps of carcinogenesis and during tumor progression. Epigenetic alterations could be used as potential biomarkers for early detection and...
3.
Hulsmann H, Rolff J, Bender C, Jarahian M, Korf U, Herwig R, et al.
Lung Cancer
. 2014 Sep;
86(2):151-7.
PMID: 25240516
Objectives: The therapeutic scheme for non-small cell lung cancer (NSCLC) patients can be improved if adapted to the individual response. For example, 60-70% of adenocarcinoma patients show response to EGFR-tyrosine...
4.
Herrmann M, Neumayr A, Essig A, Spiess J, Merk J, Moller P, et al.
Ann Thorac Surg
. 2014 Jul;
98(1):e1-3.
PMID: 24996742
Tropheryma whipplei is known as the bacterium that causes Whipple's disease, a rare systemic illness typically affecting gastrointestinal tract, joints, and central nervous system. In addition, T whipplei infection may...
5.
Linder A, Ertner C, Steger V, Messerschmidt A, Merk J, Cregan I, et al.
Interact Cardiovasc Thorac Surg
. 2012 Jul;
15(4):622-6.
PMID: 22753431
Objectives: The management of chest tubes is one of the most critical aspects in patient care in thoracic surgery, and no consensus exists regarding the ideal chest tube management strategy....
6.
Schneider K, Dietrich D, Fleischhacker M, Leschber G, Merk J, Schaper F, et al.
BMC Cancer
. 2011 Mar;
11:102.
PMID: 21426551
Background: DNA methylation in the SHOX2 locus was previously used to reliably detect lung cancer in a group of critical controls, including 'cytologically negative' samples with no visible tumor cell...
7.
Merk J, Rolff J, Dorn C, Leschber G, Fichtner I
Eur J Cardiothorac Surg
. 2011 Mar;
40(1):e29-33.
PMID: 21420313
Objective: In chemotherapy for non-small-cell lung cancer (NSCLC), some patients seem to exhibit an intrinsic resistance or develop an acquired resistance under treatment. Results on resistance markers for possible treatment...
8.
Schramm A, Wormanns D, Leschber G, Merk J
Interact Cardiovasc Thorac Surg
. 2010 Oct;
12(1):20-3.
PMID: 20940165
For resection of lung metastases computed tomography (CT) is needed to determine the operative strategy. A computer-aided detection (CAD) system, a software tool for automated detection of lung nodules, analyses...
9.
Hammer S, Sommer A, Fichtner I, Becker M, Rolff J, Merk J, et al.
Clin Cancer Res
. 2010 Feb;
16(5):1452-65.
PMID: 20179216
Purpose: Characterization of new anticancer drugs in a few xenograft models derived from established human cancer cell lines frequently results in the discrepancy between preclinical and clinical results. To take...
10.
Rolff J, Dorn C, Merk J, Fichtner I
J Oncol
. 2009 Jun;
2009:814140.
PMID: 19547715
Tumor cells that are nonsensitive to anticancer drugs frequently have a multidrug resistant (MDR) phenotype. Many studies with cell lines and patient material have been done to investigate the impact...